Painful tonic spasms and brainstem involvement in a patient with neuromyelitis optica spectrum disorder by Roman-Filip, Corina et al.
Case report
Painful tonic spasms and brainstem involvement in
a patient with neuromyelitis optica spectrum
disorder
Corina Roman-Filip a, Aurelian Ungureanu b,*, Mihaela Cernuşcă-Miţaru c
aNeurology Department, Academic Emergency Hospital, ‘‘Lucian Blaga’’ University Sibiu, Sibiu, Romania
bNeurology Department, Academic Emergency Hospital, Sibiu, Romania
cAcademic Emergency Hospital, ‘‘Lucian Blaga’’ University Sibiu, Sibiu, Romania
n e u r o l o g i a i n e u r o c h i r u r g i a p o l s k a 5 0 ( 2 0 1 6 ) 5 5 – 5 8
a r t i c l e i n f o
Article history:
Received 22 May 2015
Accepted 30 October 2015





a b s t r a c t
Neuromyelitis optica (NMO) is an inﬂammatory-demyelinating disease of the central ner-
vous system classically characterized by optic neuritis and severe myelitis. New diagnostic
criteria deﬁned neuromyelitis optica spectrum disorder as limited forms of NMO or diverse
neurologic presentations in the presence of speciﬁc antiaquaporin-4 antibodies. We report
the case of a 57-year-old woman admitted in our department for recurrent attacks of optic
neuritis, tetraparesis with severe painful tonic spasms of the left limbs and brainstem
involvement. Painful tonic spasms have been described as movement disorders associated
with multiple sclerosis, but a growing number of reports describe them in cases of NMO.
# 2015 Polish Neurological Society. Published by Elsevier Sp. z o.o. All rights reserved.
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Neuromyelitis optica (NMO) spectrum disorder (NMOSD) is a
severe inﬂammatory and demyelinating disease of the central
nervous system. The pathogenic process is attributed to
destruction of aquaporin-4 water channels by speciﬁc auto-
antibodies (NMO-IgG) [1]. NMSOD largely includes limited
forms of NMO, such as optic neuritis (ON) and long extensive
transverse myelitis, characteristic brain involvement as
hypothalamus, corpus callosum, and brainstem lesions or
Asian type of optic-spinal multiple sclerosis (MS) [2]. Painful* Corresponding author at: Neurology Department, Academic Emergen
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0028-3843/# 2015 Polish Neurological Society. Published by Elsevier Stonic spasms (PTS) or paroxysmal painful dystonia were ﬁrst
described as movement disorders associated with lesions of
the cervical spinal cord, especially in MS [3]. The character-
istics of painful tonic spasm are described as paroxysmal
episodes lasting seconds or minutes, accompanied by intense
pain and tonic postures of the limbs. Ephaptic transmission
between abnormal demyelinated tracts could explain the
spasms [4]. Recently, the presence of these manifestations
seems to be associated to NMO rather than MS or idiopathic
acute transverse myelitis [5]. Alongside with myelitis or
isolated, brainstem involvement is found in almost 32% of
the patients diagnosed with NMOSD [6].cy Hospital, 2-4 Pompeiu Onofreiu St., 550166 Sibiu, Romania.
p. z o.o. All rights reserved.
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A 57-year-old woman admitted in our department for acute
onset of painful spasms of the left limbs associated with gait
and visual disturbances. The medical history is positive for a
left ON diagnosed in 2001 that was partially responsive to
intravenous (IV) methylprednisolone with normal MRI at that
time. The patient was diagnosed at that moment with isolated
ON syndrome, but no other diagnostic workup was followed. In
December 2014, she presented bilateral decrease of visual
acuity in both eyes and progressive numbness on the left arm
followed by minor weakness with negative MRI ﬁndings for
demyelinating disease, although two small unspeciﬁc lesions
were described in the frontal white matter. Spastic gait and
mild spasticity in the lower limbs were noted. A third episode
of left ON occurred in April 2015, without any response to IV
methylprednisolone and with subsequent amblyopia. After 2
weeks, the patient presented to the emergency room with
sudden painful paroxysmal tonic ﬂexion and adduction of the
left upper limb, sparing the face, occurring every 5–10 min with
duration of maximum 10–20 s. Inconsistently, they involved
the left lower limb, were elicited by passive and voluntary
movements of the left limbs, but the majority were observed as
appearing spontaneously. There was no other history of
cardiovascular pathology (arterial hypertension, cardiac ar-
rhythmia, cardiac ischaemic disease, and dyslipidaemia),Fig. 1 – (a) T2 axial sequence showing hyperintense lesion of th
medulla oblongata. (b) FLAIR sequence with lesions at the same
medulla oblongata and brainstem–spinal junction. (d) Sagittal T2
gadolinium enhancement at the level of brainstem–spinal junctautoimmune diseases or psychiatric diseases. Expanded
neurologic examination showed spastic tetraparesis with left
side predominance, bilateral plantar clonus, brisk reﬂexes, left
eye blindness with absent pupillary reﬂex, decreased right eye
visual acuity and bilateral nystagmus. The patient accused
paraesthesia on the left hemibody without any clear sensory
loss and accused imperious micturition. The patient needed
bilateral assistance while walking. The general examination
found a blood pressure of 110/80 mmHg, rhythmic heart beats
with 76 bpm, but was otherwise normal. The acute presenta-
tion of tonic spasms raised the suspicion of epileptic seizures.
The electroencephalogram was normal during and between
the attacks, together with other neurologic ﬁndings making
the epileptic tonic seizures less plausible. Brain MRI revealed
several small frontal ischaemic lesions, T2 and FLAIR
hyperintensities at the level of the medulla oblongata with
bilateral corticospinal tracts involvement and contrast en-
hancement at the level of brainstem–spinal junction (Fig. 1).
The lesion was not considered characteristic for anterior
spinal artery infarction. An additional ﬁnding was a C5–C6
intervertebral disc protrusion with compression of the spinal
cord and subjacent post-compressive ischaemic lesion. Labo-
ratory studies showed positive serum and cerebrospinal ﬂuid
(CSF) NMO-IgG, elevated level of serum anticardiolipin anti-
bodies, and slight CSF albumin elevation with borderline
pleocytosis represented by lymphocytes. IgG quotient raised
the suspicion of intrathecal IgG synthesis and oligoclonale corticospinal tracts and paramedian structures of the
 level. (c) Sagittal FLAIR with hyperintensities at the level of
 showing extensive lesion of medulla oblongata. (e) Discrete
ion. (f) C5–C6 disc protrusion with subjacent myelopathy.
Table 1 – Serum and CSF parameters.
Test Patient values Range values
NMO-IgG (serum) 1:320 <1:10
NMO-IgG (CSF) 1:32 <1:10
IgG serum 824 mg/dl 700–1600 mg/dl
IgG CSF 4.41 mg/dl <4.0 mg/dl
Oligoclonal bands CSF Weak detection Negative
Q-IgG 5.35 <5.0
CSF albumin 0.65 g/L 0.15–0.45 g/L
CSF cellualarity 11-small lymphocytes <10
Anticardiolipin
antibodies
>120 U/ml <10 U/ml






0.64 U/ml <4.1 U/ml
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values (Table 1). The patient fulﬁlled the criteria for NMOSD
with brainstem involvement associated with PTS and com-
pressive cervical myelopathy. IV methylprednisolone was
reinitiated 1 g daily for 5 days, followed by azathioprine 50 mg
bid with good recovery of the motor deﬁcit and gait, but
without any visual improvement of the left eye. PTS were
reduced in amplitude and frequency until disappearance after
oral administration of carbamazepine 400 mg/day and baclo-
fen 20 mg/day. In August 2015, the patient was treated with IV
methylprednisolone followed by plasma exchange with
further improvement of symptoms.
3. Discussion
Brainstem involvement, with or without transverse myelitis,
is rarely seen in the classic type of NMO, and thereby, it fulﬁls
the extended criteria for NMOSD [2]. Other unspeciﬁc lesions
are seen in the hypothalamus, thalamus, splenium of corpus
callosum, but virtually all over the brain although distributed
in a different manner from MS. PTS were ﬁrst described in MS,
but recent studies showed a higher incidence in cases with
NMO and their presence, associated with ON, should rise the
suspicion of NMO [5]. Although our patient presented
episodes of ON, the MRI scan until December 2014 showed
no speciﬁc NMOSD lesions. PTS occurred relatively sudden,
consecutive to the lesions in the brainstem corticospinal
tracts. PTS must be differentiated from psychogenic attacks,
tonic epileptic seizures, paroxysmal kynesigenic dystonia,
facio-brachial dystonic seizures of LgI1 autoimmune enceph-
alitis and carpopedal spasm due to hypocalcaemia [5]. In our
case, the most important differential diagnosis was repre-
sented by focal epilepsy with tonic seizures and brainstem
ischaemia caused by upper occlusion of anterior spinal artery.
In a recent study, brainstem involvement in NMOSD is
present in almost 15% of cases, while other authors ﬁnd it
in up to 32% of the cases [6,7]. The most characteristic
brainstem lesion involves aria postrema, but in almost 2% of
the cases, the involvement of brainstem corticopinal tract
may be distinctive for NMO [7]. Carbamazepine is recognized
as the ﬁrst choice for PTS, but other drugs can be considered,as levetiracetam and gabapentine. Recently, it has been
demonstrated that patients with MS and NMO can express
positive anticardiolipin antibodies which may not be related
to the antiphospholipid syndrome, but can predict a worse
outcome regarding the advanced age of the onset [8]. In spite
of all these, one must consider that NMO patients can develop
other systemic autoimmune diseases such as systemic lupus
erythematosus and myasthenia gravis in up to 30% of the
cases [9]. The long-term therapy is represented by immuno-
suppressive therapy, out of which the most used are
azathioprine, mycophenolate and rituximab. The relapse
treatment is IV methylprednisolone and if it fails to improve
the neurological status, plasma exchange must be consid-
ered. New studies even suggest combining IV methylprednis-
olone with plasma exchange in patients with severe disease
[10]. In the earliest stages of the disease, the clinical
presentation of NMOSD can overlap or mimic other inﬂam-
matory diseases of the CNS such as MS. A correct diagnosis
(based on criteria, NMO-IgG titre, MRI scan) can prevent
further disability through a correct therapeutic management
as some immune therapies can aggravate the course of NMO
such as interferon or ﬁngolimod [11].
In conclusion, PTS associated with a history of ON may be
distinctive for NMO or NMOSD and must be early recognized in
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